Literature DB >> 10519627

Effects of misoprostol on lipoprotein (a) levels of ovariectomized rats.

A S Sonmez1, M Birincioğlu, Y Turkoz, B Adam, D Lurie, C J Chuong.   

Abstract

OBJECTIVE: To determine the effects of misoprostol on plasma lipoprotein (a) concentrations of ovariectomized rats.
DESIGN: Controlled prospective study.
SETTING: Animal research laboratory. ANIMAL(S): Four-month-old female Sprague-Dawley rats. INTERVENTION(S): Blood samples were obtained before and 60 days after ovariectomy, and the rats were divided into three groups. Group I (five rats) was treated with vehicle (water); groups II and III (nine and eight rats, respectively) were treated with oral misoprostol at 100 and 200 microg/kg/d, respectively, for 60 days, after which blood was drawn again. MAIN OUTCOME MEASURE(S): Serum lipoprotein (a) levels. RESULT(S): The median lipoprotein (a) level before ovariectomy was 10.8 mg/dL (range, 10.6-46.5 mg/dL). Sixty days after ovariectomy, the level increased significantly to 15.9 mg/dL (range, 10.6-36.9 mg/dL). After treatment, there was no change in lipoprotein (a) levels in the vehicle-treated group (range, 16.3-21.1 mg/dL); however, the lipoprotein (a) levels decreased significantly in the group treated with 100 microg/kg/d of misoprostol, from 15.4 mg/dL to 10.8 mg/dL, and in the group treated with 200 microg/kg/d of misoprostol, from 17.1 mg/dL to 10.6 mg/dL. CONCLUSION(S): Misoprostol caused a significant decrease in lipoprotein (a) levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519627     DOI: 10.1016/s0015-0282(99)00286-1

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  1 in total

1.  Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in rats.

Authors:  Dustin L Cooper; Derek E Murrell; Christopher M Conder; Victoria E Palau; Grace E Campbell; Shaun P Lynch; James W Denham; Angela V Hanley; Kenny W Bullins; Peter C Panus; Krishna Singh; Sam Harirforoosh
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.